Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
VeraDermics Inc (MANE)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$128.60-5.79%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MANE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete capital raise via public offering | A primary condition in VeraDermics Inc's published investment case. The stated target is Raise at least 3,843,790 shares at $100 per share. | Intact | failure to raise capital via public offering as planned | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a clinical-development biotechnology story, not an established earnings compounder. The long-term thesis is on watch: trial progress is substantive, but recent financial performance is weak and confidence in the overall evidence is low.
The evidence gives no usable valuation level or clear account of what the market already assumes, so whether MANE is cheap, fair, or expensive versus peers is unclear. No fragility gates fired, but that does not resolve the expectations gap or the uncertainty in valuation.
Near term, operating losses and R&D spending have increased, while recent earnings events include two reported beats and one in-line result. On the multi-year view, positive Study 304 topline results and completed enrollment in Study 306 mark development progress; management says available capital supports plans into 2030, though execution still depends on how that capital is used.
The thesis hinges on continued VDPHL01 development and whether clinical progress can support the path toward potential approval. A guidance cut or further weakening in jobs data would add near-term risk, while continued strength from healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, MANE’s clinical milestones and stated cash runway support the long-term thesis, but rising losses, weak relative financial performance, and uncertain valuation keep the evidence mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in VeraDermics Inc's published investment case. The stated target is Sufficient cash and equivalents to fund operations through 2029. |
| Intact |
| cash falls below level needed to support operations through 2029 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Positive trial data for hair loss drug | Trial data on a new hair loss drug could boost future sales. | Improving | trial data fails to show efficacy or safety concerns arise | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage and reduce operating losses and negative cash flow | It is working to reduce losses and improve cash flow. | Intact | operating losses and negative cash flow worsen beyond current levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.75 → $-2.59 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-07-25 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-07-26 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-07-27 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-07-28 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-07-29 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-07-30 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-07-31 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-01 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-02 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-03 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-04 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-05 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-06 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-07 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-08 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-09 | $-3.05 | $8,657,760 | 4 / 6 |
| 2026-08-10 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-12 | $-3.05 | $10,389,310 | 4 / 5 |
| 2026-08-13 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-14 | $-2.75 | $10,389,309 | 3 / 6 |
| 2026-08-15 | $-2.75 | $10,389,309 | 3 / 5 |
| 2026-08-16 | $-2.75 | $10,389,309 | 3 / 5 |
| 2026-08-17 | $-2.75 | $10,389,309 | 3 / 5 |
| 2026-08-18 | $-2.75 | $10,389,309 | 4 / 6 |
| 2026-08-19 | $-2.75 | $10,389,309 | 4 / 6 |
| 2026-08-20 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-21 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-22 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-23 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-24 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-25 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-26 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-27 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-28 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-29 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-30 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-08-31 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-01 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-02 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-03 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-04 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-05 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-06 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-07 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-08 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-09 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-10 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-11 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-12 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-13 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-14 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-15 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-16 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-17 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-18 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-19 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-20 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-21 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-22 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-23 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-24 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-25 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-26 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-27 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-28 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-29 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-09-30 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-01 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-02 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-03 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-04 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-05 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-06 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-07 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-08 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-09 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-10 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-11 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-12 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-13 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-14 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-15 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-16 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-17 | $-2.63 | $10,389,309 | 4 / 6 |
| 2026-10-18 | $-2.64 | $10,389,309 | 4 / 6 |
| 2026-10-19 | $-2.64 | $10,389,309 | 4 / 6 |
| 2026-10-20 | $-2.64 | $10,389,309 | 4 / 6 |
| 2026-10-21 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-22 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-23 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-24 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-25 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-26 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-27 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-28 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-29 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-30 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-10-31 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-11-01 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-11-02 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-11-03 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-11-04 | $-2.59 | $10,389,309 | 4 / 6 |
| 2026-11-05 | $-2.59 | $10,389,309 | 4 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 3 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.